Ferronova - Nanoparticle Trial Begins in Patients With Gastric and Oesophageal Cancers streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
ADELAIDE, Australia (BUSINESS WIRE) Australian biotech company Ferronova announced today that it has signed a licensing agreement with the Purdue Research Foundation (PRF) for the application of
ADELAIDE, Australia, Jan. 23, 2023 /PRNewswire/ Australian biotech company Ferronova announced today it has secured a further A$11 million to progress the company's nanoparticle platform to assist surgeons to more accurately locate and remove malignant cells during treatment of gastrointestinal and brain tumors. Irish company Renew Pharmaceuticals Limited (Renew) led an A$8 million capital raise, with a further A$3 million secured via an Australian Government Co-operative Research Centers Project (CRC-P)grant. Existing Ferronova shareholders, led by Uniseed with Artesian Venture Partners also participated. The latest round of funding for the Adelaide, South Australian headquartered company builds on seed capital and Series A funding of $4.6 million. Ferronova Chair Dr John Parker said the international investment from Renew Pharmaceuticals and existing investors, and the CRC-P grant has created a strong platform to accelerate trials in gastrointestinal and brain cancers. "R